Mundipharma International Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mundipharma International Limited
President Biden’s informal declaration that the COVID-19 pandemic is ‘over’ likely portends a formal end of the Public Health Emergency. But many of the US FDA’s COVID flexibilities don’t directly depend on that decision.
Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.
Coronavirus Notebook: Veru’s Sabizabulin Prioritized By European & US Regulators, Kinarus’s KIN001 Offers ‘Synergistic Efficacy’
Sabizabulin is the first product to be assessed under the European Medicines Agency’s expanded mandate, and has also been filed for a US emergency use authorization. At global level, the World Health Organization has issued new guidance on the use of second booster doses of COVID-19 vaccines.
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
- OTC, Consumer
- Controlled Release
- Other Names / Subsidiaries
- Cinfa Biotech GmbH
- Mundipharma Biologics S.L.
- Mundipharma EDO GmbH
- Napp Pharmaceuticals Ltd.
- Tolmar Australia Pty. Ltd.